A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). [electronic resource]
Producer: 20110621Description: 394-9 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Boronic Acids -- administration & dosage
- Bortezomib
- Canada
- Clinical Trials as Topic
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Lymphoma, Mantle-Cell -- drug therapy
- Male
- Medical Oncology -- organization & administration
- Middle Aged
- National Health Programs
- Pyrazines -- administration & dosage
- Recurrence
- Societies, Medical
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.